These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 33373409)

  • 1. Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model.
    Piscitello A; Saoud L; Fendrick AM; Borah BJ; Hassmiller Lich K; Matney M; Ozbay AB; Parton M; Limburg PJ
    PLoS One; 2020; 15(12):e0244431. PubMed ID: 33373409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.
    Fendrick AM; Fisher DA; Saoud L; Ozbay AB; Karlitz JJ; Limburg PJ
    Cancer Prev Res (Phila); 2021 Sep; 14(9):845-850. PubMed ID: 34021023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lowering the colorectal cancer screening age improves predicted outcomes in a microsimulation model.
    Fisher DA; Saoud L; Finney Rutten LJ; Ozbay AB; Brooks D; Limburg PJ
    Curr Med Res Opin; 2021 Jun; 37(6):1005-1010. PubMed ID: 33769894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing.
    Berger BM; Parton MA; Levin B
    Am J Manag Care; 2016 Feb; 22(2):e77-81. PubMed ID: 26881323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Simulated Outcomes Between Stool- and Blood-Based Colorectal Cancer Screening Tests.
    Fendrick AM; Vahdat V; Chen JV; Lieberman D; Limburg PJ; Ozbay AB; Kisiel JB
    Popul Health Manag; 2023 Aug; 26(4):239-245. PubMed ID: 37466476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
    Sharma T
    Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the Sessile Serrated Polyp Pathway on Predicted Colorectal Cancer Outcomes.
    Kisiel JB; Itzkowitz SH; Ozbay AB; Saoud L; Parton M; Lieberman D; Limburg PJ
    Gastro Hep Adv; 2022; 1(1):55-62. PubMed ID: 39129937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated impact and value of blood-based colorectal cancer screening at varied adherence compared with stool-based screening.
    Kisiel JB; Fendrick AM; Ebner DW; Ozbay AB; Vahdat V; Estes C; Limburg PJ
    J Med Econ; 2024; 27(1):746-753. PubMed ID: 38686394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
    Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
    J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
    Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
    J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People.
    Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA
    Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.
    Knudsen AB; Zauber AG; Rutter CM; Naber SK; Doria-Rose VP; Pabiniak C; Johanson C; Fischer SE; Lansdorp-Vogelaar I; Kuntz KM
    JAMA; 2016 Jun; 315(23):2595-609. PubMed ID: 27305518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Outreach Strategies for Stool-Based Colorectal Cancer Screening in a Medicaid Population.
    Karlitz JJ; Fendrick AM; Bhatt J; Coronado GD; Jeyakumar S; Smith NJ; Plescia M; Brooks D; Limburg P; Lieberman D
    Popul Health Manag; 2022 Jun; 25(3):343-351. PubMed ID: 34958279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
    Ladabaum U; Mannalithara A
    Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Projected Colorectal Cancer Incidence and Mortality Based on Observed Adherence to Colonoscopy and Sequential Stool-Based Screening.
    Meester RGS; Lansdorp-Vogelaar I; Winawer SJ; Church TR; Allen JI; Feld AD; Mills G; Jordan PA; Corley DA; Doubeni CA; Hahn AI; Lobaugh SM; Fleisher M; O'Brien MJ; Zauber AG
    Am J Gastroenterol; 2024 Jul; 119(7):1392-1401. PubMed ID: 38318949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population health outcomes of blood-based screening for colorectal cancer in comparison to current screening modalities: insights from a discrete-event simulation model incorporating longitudinal adherence.
    Forbes SP; Yay Donderici E; Zhang N; Sharif B; Tremblay G; Schafer G; Raymond VM; Talasaz A; Eagle C; Das AK; Grady WM
    J Med Econ; 2024; 27(1):991-1002. PubMed ID: 39037853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of screening and follow-up colonoscopy adenoma sensitivity on colorectal cancer screening outcomes in the CRC-AIM microsimulation model.
    Fisher DA; Saoud L; Hassmiller Lich K; Fendrick AM; Ozbay AB; Borah BJ; Matney M; Parton M; Limburg PJ
    Cancer Med; 2021 Apr; 10(8):2855-2864. PubMed ID: 33314646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Intertest Interval on Clinical Effectiveness.
    Berger BM; Schroy PC; Dinh TA
    Clin Colorectal Cancer; 2016 Sep; 15(3):e65-74. PubMed ID: 26792032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
    Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
    J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
    [No Abstract]   [Full Text] [Related]  

  • 20. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
    Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.